bioRxivCancer BiologyPreprint
Stress Induced Signaling Pathways in Burkitt Lymphoma Play Novel Mechanisms in Fate Determination and Pathogenesis of Germinal Center-Derived B-Lymphomas
Abstract
B cell receptor signaling, NF-{kappa}B signaling, BCL6 and p53 regulation are essential for germinal center (GC) B cell fate. Dysregulation of these pathways drives the pathogenesis and treatment resistance of GC-derived B-lymphomas (GCDBL). To explore how these pathways affect GCDBL fate and pathogenesis, we treated Raji cells (a GCDBL and Burkitts lymphoma) with mild hydroxyurea (HU) to simulate genotoxic stress encountered by GC B cells. Genome-wide mapping of histone H3K4me3 and p53 target analysis in HU-treated Raji cells combined with transcriptome analysis of human tonsil GC B cells identified ATAD2B (a p53 target) as differentially expressed. We found that p53 suppresses ATAD2B and ATAD2, while ATAD2 and BCL6 transcripts positively correlate in DLBCLs, suggesting that p53 regulates BCL6 in GC B cells via ATAD2 suppression. We propose that p53 regulation of BCL6 quality assures GC B cells before GC exit. Unlike BCL6 suppression of IFN-{gamma} and NF-{kappa}B signaling in GC B cells, we identified IFNGR1 as a loosely bound BCL6 target and observed loss of BCL6 regulation on genes encoding inhibitory subunits of NF-{kappa}B signaling in B-lymphoma treated with a Bruton tyrosine kinase (BTK) inhibitor. These adaptations, alongside with prevalent genetic inactivation of NF-{kappa}B inhibitory genes in DLBLCs, likely contribute to DLBCL pathogenesis and therapy resistance. Our findings highlight the pivotal role of the p53-BCL6 axis in GC B cell fate and its dysregulation in DLBCL pathogenesis and chemoresistance. Key HighlightsO_LIGenes induced in human Burkitts lymphoma under genotoxic stress are largely independent of histone H3K4me3 marks at transcriptional start sites (TSS). C_LIO_LILoss of BCL6 regulation on genes encoding components of IFN-{gamma} signaling is associated with reduced survival and the pathogenesis of DLBCL. C_LIO_LIInactivating mutations in genes encoding components of the NF-{kappa}B inhibitory subunit serve as an adaptation for DLBCL pathogenesis. C_LIO_LIBCL6 expression is correlated with ATAD2 overexpression in DLBCL and solid tumors. C_LI
- organism: human
- assay: bulk RNA-seq
- research focus: chromatin & epigenetic regulation
- research focus: gene regulatory network inference
- approach: statistical model
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- DNA replication stress-induced transcriptome of Human Burkitt lymphoma identifies MBD1 as a novel suppressor of BCL6 rearrangements in germinal center derived B-lymphomagenesis
Santosh Kumar Gothwal, Kyoko Oichai, Jacqueline H. Barlow·bioRxiv·Mar 13, 2025
- Pre-Clinical Blocking of PD-L1 molecule, which expression is down regulated by NF-κB, JAK1/JAK2 and BTK inhibitors, induces regression of activated B-cell lymphoma.
C. Vincent-Fabert, L. Roland, … N. Faumont·bioRxiv·Dec 21, 2018
- Mutations in the IgG B cell receptor associated with class-switched B cell lymphomas
L. Wasim, S. W. T. Chu, … P. Tolar·bioRxiv·Apr 12, 2024
- REL deregulation stands as a primary hit for AID-imprinted B-cells along the germinal center competition
L. Prevaud, C. Vincent-Fabert, … N. Faumont·bioRxiv·Oct 10, 2023
- Distinct Response Patterns to PHB Modulators in B Cell Lymphoma Models
Christoph Schultheiß, Maja Kadel, … Mascha Binder·bioRxiv·Jun 12, 2025
- ERBB4-mediated signaling is a mediator of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasms
A. J. Arribas, S. Napoli, … F. Bertoni·bioRxiv·Jan 1, 2023